SIGA Technologies, a biodefense firm, recently announced its financial outcomes for the second quarter of 2026, revealing a significant drop in total revenue attributed to the fluctuating schedule of product shipments. Despite this, the company successfully fulfilled its obligations under a key U.S. government agreement and is actively pursuing a new long-term procurement deal. Furthermore, SIGA has broadened its global reach through strategic partnerships and is advancing its research and development initiatives for TPOXX, an antiviral treatment for smallpox, aiming to enhance its formulations for wider demographic applicability.
The company's financial health remains robust, characterized by a substantial cash reserve and a debt-free balance sheet. This stability supports ongoing efforts to ensure readiness against biological threats, emphasizing TPOXX's critical role in national and international smallpox preparedness strategies. While the process for securing new contracts has experienced delays, SIGA maintains confidence in its market position and the continued relevance of its products in a global environment increasingly focused on biodefense.
Quarterly Performance and Strategic Initiatives
In the second quarter of 2026, SIGA Technologies recorded total revenues of $41.0 million, a decrease from $81.1 million in the same period last year, a change primarily linked to the variable nature of product delivery schedules. Product sales and supportive services accounted for $37.9 million, with notable deliveries of TPOXX to major clients in the United States, Europe, and the Asia-Pacific region. Operating income for the quarter stood at $13.9 million, down from $45.7 million in Q2 2025, and net income similarly declined to $12.5 million from $35.5 million year-over-year. Diluted earnings per share (EPS) were reported at $0.17, compared to $0.49 in the previous year's comparable period. Conversely, research and development (R&D) revenues showed growth, rising to $3.1 million from $2.0 million in the prior year, indicating continued investment in innovation.
The company's financial stability is underscored by its cash and cash equivalents, which totaled $117.6 million as of June 30, 2026, following a special dividend payment earlier in the year. Importantly, SIGA reported no outstanding debt, reinforcing its strong balance sheet. Inventory levels adjusted to $41.1 million, down from $49.1 million at the close of 2025, reflecting successful fulfillment of procurement orders. Key deliveries included $24 million of IV TPOXX to the U.S. Strategic National Stockpile, completing the final order under the 19C contract, and $13 million in international sales of oral TPOXX to customers in Europe and the Asia-Pacific region. Looking ahead, SIGA anticipates submitting its Post-Exposure Prophylaxis (PEP) program to the FDA in the first half of 2027 and expects Phase I pediatric study results by year-end 2026, which will guide further regulatory steps for a liquid formulation of TPOXX. Furthermore, management is pursuing a new international contract with a delivery target by March 2027, demonstrating ongoing efforts to expand its global market presence.
Navigating Market Dynamics and Future Outlook
SIGA Technologies is actively engaged in discussions for a new multiyear procurement contract with the U.S. government, following the successful completion of its previous contract obligations. CEO Diem Nguyen acknowledged that progress has been slower than anticipated, attributing this to leadership changes and evolving priorities within the U.S. Department of Health and Human Services (HHS), including the transition of contracts from BARDA to SNS and various open leadership positions. Despite these challenges, the company remains confident in the robust need for smallpox preparedness and TPOXX's ongoing role in national biodefense strategies, supported by continuous funding for development programs and recent product orders.
Internationally, SIGA is intensifying its focus on expanding its market footprint. This includes a recent exclusive license and distribution agreement with Hikma MENA FZE to commercialize TPOXX across the Middle East and North Africa, a region where SIGA has historically been underrepresented. Since 2024, SIGA has directly managed all international sales, marketing, distribution, and manufacturing of TPOXX, ensuring uninterrupted business continuity even after the expiration of its promotion agreement with Meridian. The company is exploring opportunities for additional international sales, with preliminary discussions targeting a new contract and delivery by March 2027 with an international customer. SIGA is also committed to advancing its Post-Exposure Prophylaxis (PEP) and pediatric programs to address vulnerabilities in smallpox preparedness, with an FDA submission for PEP targeted for early 2027 and pediatric study results expected by the end of 2026. These strategic initiatives, coupled with a strong financial position, underscore SIGA's dedication to long-term success and global health security.
